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The Potential Role of Nitric Oxide in Halting Cancer
Progression Through Chemoprevention
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Review
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Huzefa Vahora , Munawwar Ali Khan , Usama Alalami , Arif Hussain
1

School of Life Sciences, Manipal University, 2Department of Natural Science and Public Health, College of Sustainability Sciences and Humanities,
Zayed University, Dubai, United Arab Emirates

Nitric oxide (NO) in general plays a beneficial physiological role as a vasorelaxant and the role of NO is decided by its concentration
present in physiological environments. NO either facilitates cancer-promoting characters or act as an anti-cancer agent. The dilemma
in this regard still remains unanswered. This review summarizes the recent information on NO and its role in carcinogenesis and tumor
progression, as well as dietary chemopreventive agents which have NO-modulating properties with safe cytotoxic profile. Understanding
the molecular mechanisms and cross-talk modulating NO effect by these chemopreventive agents can allow us to develop better therapeutic
strategies for cancer treatment.
(J Cancer Prev 2016;21:1-12)
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INTRODUCTION

the third isoform, inducible NOS (iNOS/NOS2), produces greater
amounts of NO, reaching micromolar concentrations and lasting
hours or days. cNOS members are dependent on the calcium ion
concentrations for their activity, thus they are able to produce
lower amounts of NO for shorter durations, in comparison to
1-3
iNOS which is independent of the calcium ion concentration.
NOS enzymes are dimeric in nature and two distinct catalytic
domains, N-terminal oxygenase domain, and C-terminal
reductase domain, are present on each monomer. The substrates
binding to the N-terminal are Heme-5,6,7,8- tetrahydrobiopterin
(BH4), L-arginine, and oxygen and the substrates binding to the
C-terminal are NADPH, flavin mononucleotide, and flavin
1
adenine dinucleotide. NO production is catalyzed by NADPH and
oxygen as cosubstrates of L-arginine in the presence of NOS. The
process of NO synthesis takes place in two steps: (i)
hydroxylation of L-arginine to N-hydroxy-L-arginine by NOS
and (ii) oxidation of N-hydroxy-L-arginine to L-citrulline and
NO. The unpaired electrons of NO impart its reactivity towards

Nitric oxide (NO) is a multifunctional gaseous transmitter
which is lipophilic, as well as one of the smallest molecules found
1-3
in nature. A free radical in gaseous state functions as a
1
messenger via cyclic GMP (cGMP). It was identified as a
vasoactive small molecule in the 1980s and its cardiovascular
activities are significant in relation to its vasorelaxation function
as well as anti-thrombotic and anti-inflammatory effects. As a
gasotransmitter, it regulates many physiological functions in the
body, including neurotransmission, immune response, and
1-3
anti-pathogenic effect, although NO is quite unstable and
possess a half-life of 1 to 5 seconds in vivo.
Under normal physiological conditions, NO is produced by
three isoforms of nitric oxide synthase (NOS) (Fig. 1), Neuronal
NOS (nNOS/NOS1) and endothelial NOS (eNOS/NOS3) form the
constitutive NOS category (cNOS), activating NO production for
seconds to minutes in nanomolar concentrations. Contrastingly,
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inorganic molecules (oxygen, superoxide, or transition metals),
DNA structures, and prosthetic groups, thus portraying its
3
extensive biological activity.
The actions of NO are mainly mediated through cGMPdependent manner as well as cGMP-independent manner. The
heme component of soluble guanylyl cyclase is targeted by NO,
which further undergoes coupling with c-GMP-dependent
protein kinase G and phosphodiesterases as well as cyclic
nucleotide gated channels. In circumstances where cGMP is not
available, the actions of NO are carried out independent of cGMP
at low concentrations mainly in three ways, (i) interaction with
proteins containing transition metal, (ii) interaction with
proteins without the attached NO group, and (iii) modulation of
cell signaling by posttranslational modification, mainly by forming
S-nitrosothiol (SNO), which is achieved by coupling of a nitroso
species to a reactive thiol group in specific cysteine residues,
1-3
namely, S-nitrosylation.
Over many years, NO was considered to be oncogenic in
nature. Evidence has shown that NO plays a variety of roles in

Figure 1. The pathway elucidating the production of nitric oxide
+

(NO). NOS, NO synthase; NADP , nicotinamide adenine dinucleotide
phosphate; nNOS, neuronal NOS; iNOS, inducible NOS; eNOS, endothelial NOS.

various stages of carcinogenesis by damaging the DNA, activating
oncogenes, regulating apoptosis and metastasis, and inhibiting
enzymes for DNA repair and tumor suppressor genes. Pro-tumor
effects of NO were linked to the expression of NO-producing
2
enzymes in tumor progression. NO also portrays anti-tumor
effects by utilizing the immune defense mechanisms in animal
1,3
models of various human cancers.
Since decades, a dual role of NO has been observed and more
studies is conducted to unravel the mysterious functions of this
versatile molecule. Therefore, this review aims at showing the
recent information on NO and its role in carcinogenesis and
tumor progression.

ROLE OF NITRIC OXIDE IN CANCER
BIOLOGY
NO, a free radical and water-soluble gas produced
endogenously, regulates quite a few essential biological
4
processes. Since a few decades, an interest in NO has been
increased as a molecule involved in carcinogenesis and tumor
progression. However, a controversial facet exists in
4
understanding its role in the biology of cancer. This small
molecule possesses the quality to either induce cancer
4,5
progression or halt cancer growth and act as therapeutic agents.
In conditions where NO is at lower concentrations, it aids in
angiogenesis, which stimulates tumor progression by giving
blood flow access to the tumor and subsequently result in cell
5
proliferation (Fig. 2). On the contrary, higher levels of NO tend to
be cytotoxic to cancer cells. This is achieved by the formation of
peroxynitrite, which acts as an inducer of apoptosis and other
5
toxic species during immune surveillances. Interestingly,
peroxynitrite plays a dual role by aiding in inflammation-related
carcinogenesis through the formation of 8-nitroguanine, a
3-7
DNA-damaging entity and biomarkers.
The release of various growth factors and mediators, such as
interleukin (IL)-6, IL-8, TNF-, and NO, during the subsequent

Figure 2. Concentration-based functions of nitric oxide (NO).
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stages of tumorigenesis, changes the host microenvironment,
inducing inflammation and preventing apoptosis.3 The
calcium-independent NOS2 (iNOS) activation in almost all
nucleated mammalian cells produces NO in higher concentrations
for longer durations in comparison to its other two isoforms. The
regulation of NOS2 lies in the hands of the tumor suppressor
gene p53, which inhibits NOS2 by operating a negative feedback
mechanism against high levels of NOS2. This relation has shown
some significant implications pertaining to cancer and its
4
progression (Fig. 2). The cells transfected with iNOS showed a
substantial decrease in growth under in vitro conditions, which
was indicative of cytostatic nature of NO. This effect was
observed to be tumor-specific under in vivo conditions. Some
tumors showed less aggressive phenotypes and others displayed
8
a very aggressive nature.
The upregulation of iNOS plays the most compelling role in
the elevation and inhibition of tumorigenesis and metastasis.
Suppression of tumorigenesis by upregulation of iNOS was
9
evident in oral cancer cells. Poor patient survival is often related
to expression of iNOS in malignant melanoma stage III patients,
whereas this is observed to a lesser extent in patients with breast
cancer. Stage III ovarian cancer patients responded better towards
10
first line chemotherapy when iNOS was not expressed. This
dichotomous nature of NO implies that its level in cancers varies
quite significantly in relation to iNOS expression.

EFFECTS OF NITRIC OXIDE ON MAJOR
CANCER HALLMARKS

3

subsequently functions to be a tumor promoter during infla9
mmation-related carcinogenesis (Fig. 3).

2. Metastasis
Colonization of tumors in other sites of the body takes place in
multistep process, including local invasion, entry in the
circulation, transport to distant sites, exit from circulation, and
ultimately colony formation. Though these events appear to be
synonymous in most of the tumors, there appears to be some
tissue specific characteristics which prevail in the molecular or
phenotypic areas. One important characteristic is the colonization of a specific tumor to a specific location in the body. For
example, prostate cancer mainly metastasizes to the bone
whereas ocular melanoma establishes colonies in the liver.
Interestingly, breast cancer shows metastasis to range of tissues
such as bone, brain, liver, and lungs.
It is a well-established fact that NO plays an important role in
the process of angiogenesis/lymphangiogenesis. Not only is the
formation of these vessels undertaken by NO but its maintenance
is also looked upon by it. Thus, the expression of NOS can be
correlated to lymphatic metastasis. In particular, eNOS is the
mediator for VEGF-C induced lymphangiogenesis and is thus
involved in lymphatic metastasis. It has been demonstrated that
inhibiting eNOS pharmacologically or genetically decreases the
number of tumor cells reaching to the draining lymph node of
that tumor and thus reduces the chances of macroscopic
metastasis formation. This suggests that NO participates in the
11
early steps of lymphatic metastasis. Another important factor

1. Inflammation
It is estimated by The International Agency for Research on
Cancer that infectious disease-induced cancer cases around the
world account for approximately 18%, whereas chronic
inflammation-induced cancer cases account for approximately
6
25%.
Some of the important factors for carcinogenesis which have
been noted are infection and chronic inflammation. Inflammatory
environment results in the production of reactive nitrogen
species (RNS) and reactive oxygen species (ROS) from epithelial
and inflammatory cells, which consequently lead to oxidative
and nitrative damage of the DNA, such as 8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxo-dG) and 8-nitroguanine. These
DNA damage cause mutations in stem cells and subsequent
initiation/progression. iNOS is upregulated by transcription
factors such as hypoxia-inducible factor 1-, STAT, NF-B, and
TNF-. NF-B, plays a very crucial role for inducing iNOS, which

Figure 3. NF-B plays a crucial role in the production of nitric oxide (NO) by upregulation of nitric oxide synthase genes, which subsequently results in inflammation. HIF1, inducible factor 1-; GIC,
gap junctional intercellular communication; PDTC, pyrrolidine dithiocarbamate; PC-PLC, phosphatidylcholine-specific phospholipase;
IL, interleukin; LPS, lipopolysaccharide.
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for achieving metastasis is the epithelial mesenchymal transition
(EMT). In the earlier stages of cancer, the tumor is encapsulated
and localized by the basement membrane. As the cancer
progresses, the epithelial cells are transformed to act as
mesenchymal cells, losing their epithelial properties. Once these
transformed cells enter the circulation and reach new sites, they
undergo mesenchymal epithelial transition and then establish
1
new tumors. One of the main features of such a transformation
is the anomalous expression of cell adhesion molecules that is
mediated by NO, the paucity of which triggers the dissemination
of tumor cells. Of these, E-cadherin is associated with the early
12
stages of EMT. It was demonstrated that the downregulation of
E-cadherin is a potent prognostic factor in determining the
metastasis of gastric cancer.13
Other endocrine markers, such as estrogen-related receptor
alpha, also suppressed E-cadherin expression, thereby inducing
EMT in lung carcinoma.14 TGF- induced modulation of
15
E-cadherin aggravated ovarian cancer metastasis. Induction of
NO synthesis resulted in an upregulation in E-cadherin
16
expression. ATP receptor P2X7, another stimulus that is higher
in the extracellular microenvironment of cancer cells than
normal cells, has been recently concluded to promote tumor
12
invasion and hence be involved in metastasis. NO also impairs
the regulation of matrix metalloproteinase (MMP), which is
17,18
crucial to controlling matrix remodeling and metastasis.

3. Apoptosis
NO has been shown to induce apoptosis through posttranslational modifications.19 Studies on cervical cancer HeLa
cells, suggest the role of NO donor in increasing Fas expression,
which in turn induces apoptosis. Conversely, enormous data on
the anti-apoptotic effect of NO has been well accumulated. NO
augmented DNA damage in lung adenocarcinoma which in fact
20
triggered the anti-apoptotic machinery. The predominant
reason for the inhibition of apoptosis by NO is the occlusion of
21
caspase 3 expression. S-nitrosylation of the active cysteine rich
sites of caspases, results in oxidation of thiols (involved in cell
survival and apoptotic signaling pathway), thereby inhibiting the
21,22
Denitrosylation of caspase3 in
mechanism of apoptosis.
cancer cells by adenovirus ZD55-IL-24 has clearly demonstrated
21
the crucial role of caspase3 pathway in causing apoptosis. It was
21
also substantiated in ovarian cancer.
Upregulation of BCl2 plays a significant role in inhibiting cell
death.22 Additionally, several NO donors have shown to activate
22
anti-apoptotic pathways such as NF-B (Fig. 3). NO also activates
Ras protein, which in turn augments the anti-apoptotic Akt

23

pathway. A recent study on lung cancer revealed that prolonged
NO exposure intriguingly led to chemotherapeutic resistance to
cisplatin, through the upregulation of anti-apoptotic genes BCl2
22,23
A calcium binding protein, regucalcin,
protein kinase AKT.
interferes with the calcium signalling and hence influences the
gene expression of calcium dependent NOS, as observed in
hepatoma cells. This suppressed apoptosis, as manifested by the
24
over-activation of BCl2 and inactivation of caspases.
Consequently, NO inhibitors were analysed for their therapeutic
potential in order to promote apoptosis in nasopharyngeal
25
cancer. NO inhibitors rendered a reactivation of apoptosis and
26
angiogenesis in adenoid cystic carcinoma. It is known that NO
interferes with the DNA binding activity of many zinc finger
transcription factors through S-nitrosylation of cysteine thiol
groups and formation of SNO subsequently. Oxidation of these
thiol proteins may act as switches in signaling pathways. NO is
also thought to modulate many other thiol-containing enzymes
22
and regulatory proteins, such as NF-B.

4. Angiogenesis
Angiogenesis is a critical molecular event involved in tumor
27
progression. A wide array of genes and transcription factors act
as pro-angiogenic mediators, including NO, all of which are
27
involved in promoting neovascularization. Several studies have
27
implicated the role of NO in angiogenesis. NO stimulates
epidermal growth factor receptor (EGFR) signalling pathway, as
well as the tumor suppressor p53 and VEGF, which are collective
28
mediators that exacerbate angiogenesis. NO-mediated angiogenesis is linked to an anomaly in the regulation of angiogenesis
27,28
inhibitor thrombospondin 2.
Proliferative and angiogenic growth factors such as VEGF have
predominantly shown to affect NO signaling and hence augment
29
angiogenesis. VEGF expression was shown to induce NOS2 in
30,31
VEGF stimulates eNOS expression,
various human cancers.
which has been identified as a downstream regulator of
31,32
angiogenesis, by the activation of receptor tyrosine kinase and
32
protein kinase C signalling pathway. The relation between NO
and VEGF is reciprocal. Studies on hypoxia-induced iNOS
33
elevation possibly through NF-B, have also shown a paramount
elevation in the expression of VEGF during endometrial angio34
genesis.
The epidermal growth factor (EGF) is yet another ligand
binding to protein associated with tumor progression, owing to
35
its angiogenic potential. Previous studies have conclusively
36
shown EGF to be a coactivator in iNOS transcription. Previously,
an aberrant expression of EGFR in squamous cell carcinoma
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36

elevated the expression of iNOS. A study has further
substantiated the involvement of iNOS in EGFR up regulation in
35
gall bladder tumorigenesis. Another study showed upregulation
of eNOS through EGF like domain of CD93 protein in endothelial
37
cells. The data from previous study is associated with the
stimulation of NO production through EGFR via the
35,37
PI3K-dependent pathway.
NO upregulation is also associated with the increase in the
expression of COX-2, inhibition of which abates the process of
38,39
Another protein,
tumor angiogenesis in different cancer.
angiopoietin-like 4 (ANGPTL4), has recently shown to upregulate
iNOS expression. ANGPTL4 is associated with regulating vascular
40
permeability and is therefore crucial in promoting angiogenesis.
It was explicitly demonstrated that inducible NOS upregulated
through the application of ANGPTL4 recombinant protein in a
mouse model. The study showed the involvement of integrin/JAK/STAT3 pathway in the increase of ANGPTL4-mediated
41
iNOS elevation.
Hence, NO has been substantiated to exert its angiogenic
property via the modulation of various genes and transcriptional
42
factors that exacerbate angiogenesis.

NITRIC OXIDE IN VARIOUS CANCERS
1. Endometrial cancer
Increased NO levels are manifested in the progression of
43
endometrial carcinogenesis. Previous reports indicate the
interaction between iNOS, Bcl-2, and p53 to be a prognostic factor
43
associated with the progression of endometrial carcinoma.
Molecular studies have shown that the susceptibility to
gynecological cancers such as endometrial and cervical cancers
44
increases by inflammatory markers including NOS and COX-2.
There is a positive correlation between elevated iNOS, COX-2,
43,44
A recent case study
and angiogenesis in endometrial tumors.
on the Turkish women identified the G894T and variable number
tandem repeat (VNTR) intron 4 polymorphisms in the eNOS gene
45
to instigate endometrial cancer in such women. eNOS
expression has also been correlated with endometrial invasion.45
Various therapeutic agents administered for endometrial cancer
emphasize on their anti-inflammatory potential, especially with
43,44
respect to the downregulation of NOS expression.

2. Prostate cancer
There has been strident investigation to associate the risk of
45
prostate cancer with NO synthase levels. A plethora of
meta-analyses has identified NOS3 gene polymorphisms as

5

strong susceptibility factors for the progression towards prostate
cancer.46 A meta-analysis conducted by Zhao et al.47 suggested the
eNOS gene 894G ＞ T polymorphism to aggravate the onset of
48
prostate cancer in males. Nikolić et al. also corroborated the
involvement of eNOS or NOS3 gene in the pathogenesis of
prostate cancer. NOS3 rs1799983 polymorphism augmented the
49
risk of prostate cancer in various populations. As one of the
possible mechanisms, the involvement of the NO receptor
component, sGC1, in mediating the proliferation of prostate
49
carcinogenesis, has been surmised. Anti-cancer agents such as
gold lotion have successfully demonstrated their anti-carcino50,51
Yu et
genic potential through the downregulation of iNOS.
52
al. also elucidated the significance of eNOS as a seemingly
promising strategy for targeting anti-androgen resistant prostate
cancer. Arginine-releasing compounds such as carboxypeptidase-D increased NO production, which correlated with
53
survival and progression of prostate cancer.

3. Cervical cancer
Cervical cancer takes the second position as one of the most
common female cancers recording ＞ 200,000 deaths per year. Its
risk factors include chronic inflammation, long use of oral
contraception, smoking, multiparity, and sexually transmitted
4
diseases such as chlamydia, herpes. Cervical cells, such as
squamous, glandular epithelial, and stromal cells, generate NO,
which is a key signaling molecule shown to play an eminent role
in various physiological processes (preparing the cervix for
54
pregnancy, etc.). However, elevated levels of NO have been
reported in cervical cancer patients, thereby indicating its
mutagenic and carcinogenic potential in cervical cancer
progression. NO plays a crucial role in the progression of cervical
3
carcinogenesis through human papilloma virus (HPV). It was
concluded that NO is a pragmatic cofactor that promotes
55
HPV-induced cervical carcinogenesis. Moreover, susceptibility
to HPV infection as observed through the cytological changes in
the cervix correlates with an elevated expression of both eNOS
27
and iNOS. Of these, iNOS, plays a prominent role in tumor
progression, by promoting angiogenesis and thus regulating the
56
level of VEGF. This explanation was corroborated by an iNOS
knockdown experiment in HeLa cells that reduced their
57
proliferation. High NO concentrations impair the migration of
neutrophil migration, which express receptors necessary for
57
extricating tumor cells in cervical neoplasia. NO also encumbers
the success rate of conventional treatment therapy. In a study by
58
Chen et al., overexpression of iNOS along with COX-2 correlated
with diminished survival rates of cervical cancer patients on

6
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radiotherapy regime.

4. Breast cancer
Breast cancer is the predominant cause of mortality among
women worldwide. Tumorigenesis in the mammary gland has
been reported to correlate with VNTR 4 a/b polymorphism that
59
regulate eNOS expression. NO can modulate tumor aggression
in breast carcinoma through the inhibition of enzymes linked to
60,61
Moreover, iNOS inhibits DKK
DNA repair machinery.
glycoprotein, which is crucial to regulating the Wnt/-catenin
pathway.8 Abrogation of this pathway is activated in several
62
tumors, including breast cancer. A diagnostic evaluation of
inflammatory markers associated with breast cancer prognosis
includes NO as well.63 Apoptosis of triple negative breast cancer
cells have been attained through the modulation of iNOS
64
activity. Knockdown of genes regulated by NO signaling
pathway ameliorated breast tumor metastasis.65 Augsten et al.66
demonstrated an upregulation of NOS levels in
CXCL14-expressing cancer-associated fibroblasts which triggers
tumor growth and metastasis. The manifestation of
chemo-resistance as well as metastasis in breast cancer cells are
rendered through NO elevation, which therefore results in poor
67
survival of patients. Importantly, NO induces tamoxifen-resistance
68
in ER positive breast cancer.

5. Head and neck cancer
One of the major causes of morbidity and mortality and the
sixth most common cancer type is the oral squamous cell
carcinoma. Its high occurrence is affiliated with the use of tobacco
and tobacco-related products such as cigarettes. Tobacco
components act as initiators of inflammation which
consequently are responsible for the production of RNS. RNS
hamper the antioxidant protective system and induce lipid
4
peroxidation in tobacco users. Head and neck cancer (HNC)
shows an increased level of NOS activity which is correlated with
high levels of cGMP levels and vascularization in the tumor mass.
Lymph node metastases are associated with microvessel density
as well as high NOS activity, which is indicative of high metastatic
69
nature. Mutations in p53 have been correlated with
70
overexpression of iNOS as well as oxidative stress. Patients with
oral pre-cancer displayed high levels of NO2 and NO3 as well
71
individuals with tobacco usage showed similar results. This is
indicative of the injuries caused by the RNS in patients with
pre-cancer as well healthy individual with tobacco usage. This
aspect has a clinical relevance in acting as a biomarker of
inflammation and can be utilized for the estimation of cancer

4

risk. Ethanol stimulates NO generation and is important to the
etiology of a few cancer including HNC.4

6. Lung cancer
Lung cancer is one of the leading causes of mortality and
71
morbidity at present. The primary cause for this devastating
disease is tobacco smoke, which triggers chronic inflammation of
the airway and activates leukocytes that produce ROS and NO at
higher levels. An increased level of nitrite, nitrotyrosine, and NO
72
are noted in lung cancer patients. Substantially higher levels of
iNOS are observed in lung tissues of smokers in comparison to
4
the non-smokers. It is observed that cigarette smoke has about
14
73
10 ROS and 700 ppm NO in a single puff. A high level of NO is
present in the exhaled air from the lung cancer patients in
comparison to healthy controls. A significantly high level of
nitrated proteins were found in the serum correlating to the
73
presence of nitrosative and oxidative stress.
It was also demonstrated that cells treated with NO over a long
period of time increased the number of filopodia per cell and cell
division cycle 42 protein was also found to be in higher
concentration. This shows that long term exposure of cells to NO
has a unique effect on migratory potential of the cells via
73
caveolin-1-dependent mechanism. NO works towards carcinogenesis by nitrating proteins. Nitration of proteins takes place by
the reaction of NO and its metabolites with ROS which lead to
production of high caliber nitrating agents. One of the main
chemical modifications occurring due to oxidative/nitrosative
stress is the formation of 3-nitrotyrosine in proteins. NO at high
levels deactivates p53 which consequently aids in the progression
of cancer and it stands true in 90% of lung cancer cases , which are
4
found to be p53 defective.

7. Gastric cancer
Having witnessed abundant advances in the field of
therapeutics, some diseases still remain as a global threat to life:
one among them is gastric cancer. It is well established that the
carcinogenesis of the gastric tissues is positively attributed to
4
infection of Helicobacter pylori and excessive intake of salt
whereas there has been a debate on whether alcohol
consumption and tobacco smoking are associated with the
neoplastic transformation. Interestingly, all the three isoforms of
NOS (nNOS, iNOS, and eNOS) express in the gastric canal. High
expression levels of iNOS and eNOS have been observed in
4
human colorectal cancers. Tumor angiogenesis plays a vital role
in progression of the cancerous cells and result in metastasis. Cell
proliferation promotes by supplying blood vessels to the tumor
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by VEGF, which aids in the formation new blood vessels. The
levels of VEGF correlate with the levels of NO. High serum VEGF
levels were noted in gastric cancer patients in comparison to the
healthy control group, which directly indicates that NO plays an
important role in the progression of cancer by providing means of
better blood supply and ways for cancer cells to establish new
74
centers via metastasis.

8. Brain tumors
Many vital physiological activities, such as vasculature and
neurotransmission, are influenced by NO. Many disorders of the
central nervous system portray NO as an important mediator of
neurotoxicity. nNOS expression is an indicator for differentiation of brain tumor and malignancy. Unexpected high NO levels
are observed in central nervous system malignancies and this
suggests that there is some correlation between NO production
4
and pathophysiological processes of tumor progression.

CHEMOPREVENTION AND ITS ROLE FOR
NITRIC OXIDE PRODUCTION
Conventional chemotherapeutic drugs are a part of standard
cancer treatment regime. While several drugs have displayed
anti-inflammatory and pro-apoptotic activity via alleviation of
75
NO signalling, patients administered with drugs, namely
tamoxifen citrate, capecitabine, and epirubicin, have incurred
cardiovascular and other cytotoxicity through the aggravation of
76
NO signaling. Moreover, chronic inflammation, which is
involved in the elevation of markers such as cytokines and NO, is
associated with immunosuppression in cancer, thereby hindering
77
the survival outcome of patients. Owing to these complexities,
chemoprevention may be the new buzzword and hence there
have been ongoing attempts to evaluate multidimensional
involvement of chemopreventive agents through targeting
78
various hallmarks of cancer (Fig. 4). Chemoprevention focuses
on the identification of certain dietary agents that can, if not
completely cure, alleviate cancer proliferation in the body.
Certain dietary agents and phytochemicals with chemopreventive potential involve anti-inflammatory mechanisms that
reduce NO levels and consequently help to inhibit the function of
genes and markers involved in tumor progression, thereby
abating the process of carcinogenesis. Many phytochemicals such
as flavonoids showed to inhibit lipopolysaccharide-stimulated
79
iNOS expression. Therefore, unravelling the potential of
promising natural agents with chemopreventive capabilities may
help to alleviate NO induced inflammation observed during

7

78,80

carcinogenesis.

REVERSAL OF CANCER HALLMARKS
THROUGH CHEMOPREVENTION
As mentioned above, the alluring effects of various chemopreventive agents in reinstating NO levels that control the
successive stages of tumor progression has been recognized.81 A
colossal amount of data indicated that chemopreventive agents
with antioxidant and anti-carcinogenic potential, reduced
NO-induced modulation of genes which influence cancer
82
proliferation, metastasis, and angiogenesis. Hence, based on
the molecular markers targeted at various stages of tumor
progression, chemopreventive agents have been classified as
83
non-steroidal anti-inflammatory drugs (NSAIDs).
Some NSAIDs act as COX-2 inhibitors that play an antiinflammatory and anti-angiogenic role.83 COX-2 triggers the
inflammatory process during NO-mediated tumor proliferation.
COX-2 suppression has shown to simultaneously inhibit NO
levels. Celecoxib, a COX-2 inhibitor, has been proven to be an
effective chemopreventive agent against breast and colon cancer
to alleviate angiogenesis and metastasis in combination
treatment with anti-angiogenic agents. Curcumin, inhibits
extracellular-signal regulated kinase (ERK) and consequently
82
hinders translation of NF-B and COX-2, both of which are
82
involved in the regulation of NO. Curcumin attenuates NO and
COX-2 through a post transcriptional event, thereby aiding in
83
colon cancer prevention through its anti-inflammatory efficacy.
Another COX-2 inhibitor, resveratrol, suppressed inducible NO
levels in SW480 human colon cancer cells by phosphorylating of
84
inhibitor of B (IB). Soyasaponin, an another anti-inflamma-

Figure 4. Molecular targets of chemo-preventive agents.

8
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tory agent, was also shown to reduce NO production, by reducing
COX-2 and inducible NOS expression in prostate colon and breast
85
cancers. Aspirin enhances the endogenous production of
maspin, which inhibits invasion and metastasis in breast tumors,
86
via the restoration of NO production. Aliphatic isothiocyanates,
such as sulphorafane (SFN) abundant in cruciferous vegetables,
were indicated in a study to down regulate the expression of iNOS
and COX-2 through the thiol-dependent inhibition of DNA
87
binding to NF-B. Similar results were obtained and further
suggested that a combination of SFN and curcumin may be more
effective in synergistically downregulating the activity of
88
inflammatory markers such as TNF, IL-1 and NO.
Anti-estrogenic agents, such as genestein, also inactivated NF-B
via downregulation of Akt in numerous cell lines.89 Epigallocatechin gallate (EGCG) protects cellular damage, which is partly
imparted through NO elevation, by blocking inflammatory
8
kinases such as AKT and PI3K.
The efficacy of numerous chemopreventive agents in
inhibiting angiogenesis have been investigated since long
84
before. To elucidate their anti-angiogenic mechanism,
researchers sought to correlate NO with other pro-angiogenic
88
factors such as VEGF in various experiments. VEGF exacerbates
NO production during angiogenesis.86 Natural dietary VEGF
87
inhibitors have therefore shown to control tumor angiogenesis.
VEGF pathway-based therapy has been successful in curbing
88
down angiogenesis by decreasing NO production. Flavolignans
such as silibinin exerted their anti-angiogenic role by
80
downregulating iNOS activity in lung cancer. Dietary alkaloids,
such as harmine, inhibited the anomalous elevation of
89
pro-angiogenic factors, especially NO and VEGF. iNOS
aggravates angiogenesis by the activation of PI3K-AKT-mTOR
pathway in melanoma and several other cancers. This activation

was reversed by treatment with magnolol, a hydroxylated
biphenyl compound extracted from Magnolia officinalis.
Magnolol was able to avert the angiogenic events induced by
VEGF, such as the activation of Akt/eNOS pathway. However,
since reduction in endothelial NO bioavailability has been
associated with hypertension in patients with VEGF therapy,
further research is required to prove its efficacy. Interestingly,
reduction in endothelin-1 in patient samples with VEGF therapy
was able to ameliorate the elevated blood pressure levels.
Certain dietary agents render themselves as anti-metastatic
agents by targeting NO levels. NO has been implicated in the
activation of c-Src (a non-receptor tyrosine kinase) which is
90
involved in tumor progression and metastasis. Studies in breast
cancer elucidated its mechanism by showing that c-Src activation
91
by -estradiol, depended on the production of NO.
Furthermore, the NO-mediated c-Src activation suppressed
E-Cadherin expression.92 Consequently, loss of E-cadherin
expression is a hallmark feature in cancer that instigates the
90
disruption of cell-cell adhesion and hence tumor cell invasion.
Modulation of E-cadherin in conjunction with overexpression of
TGF-1 has especially shown to play a critical role in
90
carcinogenesis of the urinary bladder. Among the many
available chemopreventive agents (Table 1), EGCG’s inhibitory
role in the invasion of A375 cells was attributed, to the
upregulation of E-cadherin in a concentration and time
8
62
dependant manner. Du et al. suggested the anti-metastatic
effect of EGCG by the enhanced expression of p27 and E-cadherin
in human glioma cells. Another study demonstrated that the
suppression of cell migration by EGCG in bladder cancer was
through the inactivation of N-cadherin, which was in turn due to
21
inactivation of Akt signalling. Zhang et al. elucidated the
eminent role of EGCG in inhibiting angiogenesis, via the

Table 1. Chemo-preventive agents and their molecular targets
Chemo-preventive agents

Source

Curcumin

Turmeric

Gingerol
Epigallocatechin gallate
Capsaicin
Genistein
Resveratrol

Ginger
Green tea
Pepper
Soybeans
Red grapes

Quercitin
Sulforaphane
Lycopene
Eugenol

Caper
Broccoli
Tomato
Cloves

Molecular target
Inhibition of IB, ERK1/2
downregulation of NF-B
Inhibition of cell development factor
Inhibition of AP1, VEGF, STAT3, and NF-B
Induction of apoptosis and inhibition NF-B expression
Suppression of NF-B and AKT
Inhibition of PKC and AP1 transformation
Reduced NF-B expression
Caspase-dependent apoptosis
Inactivation of NF-B binding with DNA.
Upregulation of antioxidant response element
Downregulation of Bcl-2, COX-2, and IL-1.

ERK, extracellular-signal regulated kinase; PKC, protein tyrosine kinase; AP1, activator protein-1; IL-1, interleukin 1.

Reference No.
93, 94
93,
93,
93,
93,
93,

94
94
94
94
94

93,
93,
93,
93,

94
94
94
94
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downregulation of vascular endothelial-cadherin and Akt.
Other agents such as dithiolethione modified valproate, sulindac
and diclofenac, were collectively shown to enhance E-cadherin
86
expression in non-small cell lung cancer.
Like E-cadherin, MMP is also involved in the loss of cellular
adhesion, thereby enabling the cells to metastasize. Previous
studies have shown a reciprocal relationship between NOS and
MMP levels, which collectively exacerbate tumor invasion and
25
metastasis. Knockdown experiments by Zhang et al. confirmed
that decreased production of L-arginine-induced NO,
subsequently decreased the expression of MMP-1 levels in
melanoma cells. The activation of transcription factors, namely
ERK-1/2 and AP-1, elucidated the notorious role of NO towards
89
triggering cancer metastasis via MMP-9. Furthermore, Patruno
92
et al. provided further insight into the mechanism of MMP
upregulation. Based on their results on human acute monocytic
leukemia cells, they indicated an aberration in iNOS through
environmental influence. This affected the expression of tissue
inhibitors of MMPs involved in the regulation of MMPs.
Ipobscurine, an indole alkaloid, suppressed the activation of
genes involved in metastasis and tumor proliferation, namely
MMPs, caspase-3, p53, Bax, and transcription factors such as
91-94
NF-B.
Several chemopreventive agents, including terpenes,
sulphides, phenols, organic acids, and other macromolecules,
modulate carcinogen detoxification enzymes. For example, the
major mechanism by which SFN and other organosulfur
compounds exert their anti-carcinogenic potential is by
upregulating the transcription of glutathione S-transferase P
(GSTP), a phase II detoxification enzyme, via the activation of
85
c-jun and Nrf2 binding to enhancer element enhancer I of GSTP.
Several studies suggest the upregulation of GSTP1 in various
86
tumors. Downregulation of GSTP1 resulted in increased
92
susceptibility to gastric, colorectal, and lung cancer progression.
Apart from its role in detoxification, GST enzymes are also
8
involved in the regulation of NO pathways. Kenneth and his
co-workers used a GST-null mice to demonstrate the significant
elevation in the level of inflammatory genes, including iNOS in
87
colon cancer. GST- is over-expressed in oral cancer in
88
conjunction with NO obtained from cigarette smoke. Various
chemopreventive agents, such as green tea extracts, broccoli
sprout extracts, EGCG, phenethyl isothiocyanate, and benzyl
isothiocyanate, were also able to augment phase II enzyme
7
activity (GSTP1), in lung cancer. SFN activated Nrf, involved in
the induction of phase 2 detoxification enzymes which
88
predominantly downregulates during oncogenesis.

9

CONCLUSION
The chemopreventive agents induce NO production and thus
facilitate apoptosis. Thus, chemoprevention shows a potential to
be used for cancer therapeutics in the near future and one of its
main target would be NO.
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